Paradigm Strategies in Wealth Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Paradigm Strategies in Wealth Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-818	Closed	-$60K	–	186
2021 Q2	$60K	Hold	818	–	–	0.05%	90
2021 Q1	$56K	Buy	+818	New	+$56.4K	0.05%	89

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OPS

Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Paradigm Strategies in Wealth Management's PPH Position: Q3 2021 in Review

Paradigm Strategies in Wealth Management sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2021, closing a stake of 818 shares — an estimated $60K sold.

Paradigm Strategies in Wealth Management first reported a position in PPH in Q1 2021 and held it in 2 quarters. The position peaked at $60K in Q2 2021. 51 funds tracked by Wall St. Rank hold PPH as of Q3 2021.

Paradigm Strategies in Wealth Management reported no remaining VanEck Pharmaceutical ETF position as of Q3 2021 after selling out during the quarter.
Paradigm Strategies in Wealth Management sold 818 VanEck Pharmaceutical ETF shares in Q3 2021, an estimated $60K.
Paradigm Strategies in Wealth Management first reported a position in VanEck Pharmaceutical ETF in Q1 2021 and held it in 2 quarters.
Paradigm Strategies in Wealth Management's VanEck Pharmaceutical ETF position peaked at $60K in Q2 2021.
51 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2021.

Based on Paradigm Strategies in Wealth Management's 13F filing for Q3 2021, filed 15 Oct 2021.